A Single Dose of an Inhibitor of Cyclooxygenase 2, Meloxicam, Administered Shortly after Irradiation Increases Survival of Lethally Irradiated Mice

• Authors: HOFER M.; POSPÍŠIL M.; DUŠEK Ladislav; HOFEROVÁ Z.; WEITEROVÁ L.
• Year of publication: 2011
• Type: Article in Periodical
• Magazine / Source: Radiation Research
• MU Faculty or unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1667/RR2614.1
• Field: Biophysics
• Keywords: GAMMA-IRRADIATION; HEMATOPOIETIC RECOVERY; G-CSF; INDOMETHACIN; TOXICITY
• Description: This study extends earlier findings of the authors demonstrating that meloxicam, a selective inhibitor of cyclooxygenase 2, supports hematopoietic recovery in sublethally irradiated mice and is radioprotective when given before irradiation. We report here that when meloxicam was administered in a single dose 1 h after a lethal 9-Gy whole-body dose, an increased 30-day survival was achieved. Additional studies showed that administration of meloxicam 24 h after lethal irradiation is ineffective and its repeated administration deleterious. Possible mechanisms of the therapeutic effects of meloxicam administered early after irradiation are discussed.

Related projects

• Activation of adenosine receptors combined with cyclooxygenase inhibition in modulation of radiation-induced myelosuppression